登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
ClinicalTrials.gov 上登记的一项胶质瘤开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07306299,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
16 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed WHO Grade III or IV glioma harboring one or more of the following mutations: H3.3K27M, H3.1K27M, H3.3G34R, BRAF V600E, PIK3CA H1047R, IDH1 R132H, or EGFRvIII.
入选标准第 3 条
Recurrent or progressive high-grade glioma, defined as a CNS WHO Grade 3-4 glioma confirmed by post-surgical histopathology, with documented recurrence or progression per RANO criteria on MRI following standard therapy (radiotherapy plus temozolomide chemotherapy).
入选标准第 4 条
Karnofsky Performance Status (KPS) ≥50. For subjects with spinal cord lesions, functional deficits due to paralysis will not be considered in the KPS assessment.
入选标准第 6 条
Absolute Neutrophil Count (ANC) ≥1.5 × 10⁹/L
入选标准第 9 条
Platelet count (PLT) ≥100 × 10⁹/L
入选标准第 10 条
Hemoglobin (HGB) ≥90 g/L
入选标准第 11 条
Alanine Aminotransferase (ALT) ≤2.5 × Upper Limit of Normal (ULN)
入选标准第 13 条
Aspartate Aminotransferase (AST) ≤2.5 × ULN
入选标准第 14 条
Total Bilirubin (TBIL) ≤1.5 × ULN
入选标准第 15 条
Serum creatinine ≤1.5 × ULN OR estimated creatinine clearance ≥50 mL/min (calculated using the Cockcroft-Gault formula)
入选标准第 17 条
Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN
入选标准第 19 条
International Normalized Ratio (INR) ≤1.5 × ULN
入选标准第 20 条
History of other malignancies within the past 5 years (except appropriately treated carcinoma in situ of the cervix or non-melanoma skin cancer).
排除标准第 1 条
Human Immunodeficiency Virus (HIV) antibody
排除标准第 5 条
Hepatitis C Virus (HCV) antibody with detectable HCV RNA
排除标准第 6 条
Hepatitis B Surface Antigen (HBsAg) with HBV DNA ≥2000 IU/mL
排除标准第 7 条
Negative pregnancy test for women of childbearing potential (WOCBP); non-pregnant and non-lactating females; both male and female participants must agree to use highly effective contraception and have no plan for pregnancy within 6 months after study entry.
入选标准第 26 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07306299,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Adequate compliance, ability to comprehend the clinical trial, and provision of written informed consent. Male or female, aged ≥16 years. Histologically or cytologically confirmed WHO Grade III or IV glioma harboring one or more of the following mutations: H3.3K27M, H3.1K27M, H3.3G34R, BRAF V600E, PIK3CA H1047R, IDH1 R132H, or EGFRvIII. Recurrent or progressive high-grade glioma, defined as a CNS WHO Grade 3-4 glioma confirmed by post-surgical histopathology, with documented recurrence or progression per RANO criteria on MRI following standard therapy (radiotherapy plus temozolomide chemotherapy). Life expectancy ≥3 months. Karnofsky Performance Status (KPS) ≥50. For subjects with spinal cord lesions, functional deficits due to paralysis will not be considered in the KPS assessment. Absence of significant bone marrow, cardiac, pulmonary, or renal dysfunction, defined as: Hematologic (without transfusion or hematopoietic growth factor support within 14 days): Absolute Neutrophil Count (ANC) ≥1.5 × 10⁹/L Platelet count (PLT) ≥100 × 10⁹/L Hemoglobin (HGB) ≥90 g/L Hepatic Function: Alanine Aminotransferase (ALT) ≤2.5 × Upper Limit of Normal (ULN) Aspartate Aminotransferase (AST) ≤2.5 × ULN Total Bilirubin (TBIL) ≤1.5 × ULN Renal Function: Serum creatinine ≤1.5 × ULN OR estimated creatinine clearance ≥50 mL/min (calculated using the Cockcroft-Gault formula) Coagulation: Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN International Normalized Ratio (INR) ≤1.5 × ULN Other: Left Ventricular Ejection Fraction (LVEF) ≥50% without clinically significant pericardial effusion on echocardiogram No clinically significant electrocardiogram (ECG) abnormalities Baseline oxygen saturation >92% on room air Adequate immune function, defined as receiving dexamethasone ≤2 mg/day within the 3 days prior to screening without severe lymphopenia. Negative pregnancy test for women of childbearing potential (WOCBP); non-pregnant and non-lactating females; both male and female participants must agree to use highly effective contraception and have no plan for pregnancy within 6 months after study entry.排除标准:Exclusion Criteria:
History of other malignancies within the past 5 years (except appropriately treated carcinoma in situ of the cervix or non-melanoma skin cancer). History of hypersensitivity to chemotherapy agents or radiosensitizers used for central nervous system or head and neck cancers. History of severe allergic reactions to vaccines or any components of the investigational product. Positive serology for: Human Immunodeficiency Virus (HIV) antibody Hepatitis C Virus (HCV) antibody with detectable HCV RNA Hepatitis B Surface Antigen (HBsAg) with HBV DNA ≥2000 IU/mL Treponema pallidum (TP) antibody with a positive confirmatory test (e.g., RPR/TPPA) Active, uncontrolled infection, active tuberculosis, or active immunosuppressive disease. Any concurrent non-malignant illness or psychiatric condition that would preclude safe protocol participation; uncontrolled cardiovascular disease (e.g., coronary artery disease, angina, myocardial infarction, significant arrhythmias). Inability or unwillingness to provide informed consent or participate voluntarily. Concurrent participation in another interventional clinical trial or participation within 3 months prior to screening. Severe infection or signs/symptoms of active infection within 2 weeks prior to the first dose of the investigational product. Administration of a live-attenuated vaccine within 4 weeks prior to the first dose. History of solid organ or hematopoietic stem cell transplantation. Any other condition that, in the opinion of the investigator, would jeopardize the subject's safety or compliance with the study protocol.
引自 ClinicalTrials.gov, NCT07306299, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07306299,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。